Fmr LLC Increases Stake in Hologic, Inc. (NASDAQ:HOLX)

Fmr LLC grew its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 64.0% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,572,545 shares of the medical equipment provider’s stock after purchasing an additional 2,174,093 shares during the quarter. Fmr LLC owned approximately 2.40% of Hologic worth $453,940,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in HOLX. Wolff Wiese Magana LLC purchased a new position in Hologic during the 3rd quarter valued at about $25,000. Innealta Capital LLC purchased a new position in shares of Hologic during the second quarter valued at approximately $25,000. iA Global Asset Management Inc. purchased a new position in shares of Hologic during the first quarter valued at approximately $37,000. First Horizon Advisors Inc. lifted its stake in Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares during the period. Finally, Sunbelt Securities Inc. bought a new stake in Hologic in the second quarter valued at $37,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analyst Ratings Changes

HOLX has been the topic of a number of research analyst reports. UBS Group boosted their price objective on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Raymond James boosted their price target on shares of Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Leerink Partners lowered their price objective on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Royal Bank of Canada upped their target price on Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a report on Tuesday, November 5th. Finally, StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $89.91.

Hologic Trading Up 0.1 %

Hologic stock opened at $79.50 on Friday. Hologic, Inc. has a 12 month low of $67.59 and a 12 month high of $84.67. The company has a market capitalization of $18.47 billion, a price-to-earnings ratio of 23.87, a price-to-earnings-growth ratio of 2.50 and a beta of 0.98. The business’s fifty day simple moving average is $80.22 and its two-hundred day simple moving average is $78.42. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.01. The company had revenue of $987.90 million for the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. Hologic’s revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.89 EPS. As a group, equities analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.